Peter Greenleaf, MBA
Director, President and CEO
Peter Greenleaf currently serves as the President, Chief Executive Officer and member of the Board since April 29, 2019. From March 2018 to April 2019, Peter served as the Chief Executive Officer and a member of the board of directors of Cerecor, Inc. (NASDAQ: CERC). From March 2014 to February 2018, Peter served as CEO and Chairman of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a company that focused on the development and commercialization of medicines to meet major unmet medical needs of patients worldwide until it was sold in February 2018 to U.K. pharmaceutical giant Mallinckrodt plc. Peter also served as Chief Executive Officer and a member of the board of directors of Histogenics Corporation, a regenerative medicine company. From 2006 to 2013, Peter was employed by Medlmmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. From January 2010 to June 2013, Peter also served as President of Medlmmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group. Prior to serving as President of Medlmmune, Peter was Senior Vice President, Commercial Operations of MedImmune, responsible for its commercial, corporate development and strategy functions. Peter has also held senior commercial roles at Centocor, Inc. (now Janssen Biotechnology, Johnson & Johnson) from 1998 to 2006, and at Boehringer Mannheim (now Roche Holdings) from 1996 to 1998. He is also currently a member of the board of directors of Antares Pharmaceuticals, Inc. (NASDAQ: ATRS), and was the Chairman of the board of directors of BioDelivery Sciences International, Inc (NASDAQ: BDSI) until its sale to Collegium Pharmaceuticals in March 2022. Peter earned an MBA degree from St. Joseph’s University and a BS degree from Western Connecticut State University.
Max Donley, MBA
Executive Vice President, Operations and Strategy
Max Donley most recently led Human Resources, Information Technology and Facilities at Senseonics. Prior to that, Max was Executive Vice President of Global Human Resources, Information Technology, and Corporate Strategy at Sucampo Pharmaceuticals until its acquisition in February 2018. Prior to that, Max served as Executive Vice President, Human Resources and Corporate Affairs at MedImmune, where he provided business-integrated leadership and delivered professional tools, programs and services to optimize MedImmune’s human capital investments worldwide.
Max received his B.A. from University of Michigan and his MBA from the George Mason University.
Sue Evans, MBA, RAC
Senior Vice President, Global Regulatory Affairs
Sue Evans joined Aurinia in 2014 and has more than 26 years of experience in the pharmaceutical and biotech industry, spanning multiple roles; regulatory affairs, global program management, business development, process improvement, and analytical chemistry. At Aurinia, she is responsible for global regulatory strategies and submissions leading a team of 11, and recently led the Aurinia submission team to a successful NDA approval for LUPKYNIS™. Sue began her career in 1996 at 3M Drug Delivery Systems in the UK, where she held a number of positions of increasing responsibility until assigned the Global Program Manager for two late-stage development asthma products working with large pharmaceutical clients, including Sanofi, Nycomed (now Takeda), Novartis, and Schering Plough (Alvesco & Dulera both successfully commercialized). Following her time at 3M, Sue worked at Vectura (UK Specialty Pharma company) as a regulatory specialist where she gained further experience in generics, asthma inhalers and EU & US regulatory affairs. Sue emigrated to Canada with her family in 2011 where she gained her MBA from Vancouver Island University. Sue also holds a Bachelor of Science (BSc) Chemistry from Loughborough University, UK and is Regulatory Affairs Certified (RAC).
Chief Commercial Officer
Scott Habig joins Aurinia as Chief Commercial Officer with more than 20 years of global and U.S. sales and marketing experience and relevant expertise in Rheumatology and Lupus markets. A transformational leader and collaborator, Scott has an accomplished history of engaging and inspiring salesforces, creating patient-centric environments, and blending strategic leadership and forecasting abilities to exceed expectations and business goals. Over the past ten years, Scott has held numerous leadership roles at UCB, Inc and most recently was Head of Global SLE, maintaining full responsibility for pre-launch and commercial launch activities of a novel CD40 ligand currently in Phase III of clinical development for Systemic Lupus Erythematosus (SLE). His previous roles include Vice President, Sales at Human Genome Sciences, where he led the development and execution of organizational capabilities and infrastructure to support the company’s first sales team and led organizational and operational initiatives to guide the first major Lupus drug launch in more than 50 years. Prior to this role, Scott spent nine years at Centocor, Inc. where he led development and execution of sales and marketing strategies for one of the first biologic therapies approved for multiple autoimmune disorders. Under Scott’s sales and marketing leadership at Centocor, the company transformed a multimillion-dollar pipeline into a multibillion-dollar product. Scott received his B.A. from the University of Akron.
Volker Knappertz, M.D.
Executive Vice President, Research and Development
Dr. Volker Knappertz is the Executive Vice President of Research & Development, joining Aurinia in July 2022. He leads the entirety of Aurinia’s R&D effort, including pre-clinical research and pharmacology, clinical development, patient safety, medical affairs, regulatory affairs, and all other R&D functions.
Dr. Knappertz is a recognized leader in the drug development community and has achieved numerous INDs and product approvals. He served on several committees involving pharmaceutical, regulatory and academia medicine development. His work has been published in leading peer reviewed journals, including Proceedings of the National Academy of Sciences, JAMA Neurology, Lancet Neurology, BMJ and Neurology. He currently serves as an independent director on the board of Sutura Therapeutics, UK, an innovation-driven company developing RNA-targeted precision gene medicines to treat debilitating or life-threatening medical conditions.
Prior to joining Aurinia, Dr. Knappertz served as the Executive Vice President of Research & Development and Chief Medical Officer at GW Pharmaceuticals, a global biopharmaceutical company targeting medicines for rare and orphan diseases as well as epilepsy, multiple sclerosis, schizophrenia, autism spectrum disorders and neurodegenerative diseases. He was instrumental in driving the transformation of GW from a botanical pharmaceutical company to a fully integrated biopharmaceutical R&D and marketing organization, which was achieved by gaining the first FDA approval of Epidiolex, a treatment for rare developmental childhood onset forms of epilepsy and building a pipeline of novel small molecule CNS therapeutics.
Before joining GW, he was the Vice President of clinical development for multiple sclerosis, immunology, oncology and biosimilar products at Teva Pharmaceuticals achieving several drug approvals and business development deals. During the first decade of his drug development career Volker held R&D positions in multiple therapeutic areas including CNS, CV and immunology at Astrazeneca and Bayer.
Dr. Knappertz received his magna cum laude doctorate and Medical Degree from Cologne University. He has served as adjunct professor in Neurology at the University of Pennsylvania and Heinrich-Heine University in Düsseldorf. He was trained in Neurology at Yale University, fellowship trained at Wake Forest University and is a US board certified neurologist.
Chief Business Officer
Mike Martin, who most recently served as Chief Operating Officer, has spearheaded all of our business development efforts, including partner management, out-licensing, in-licensing, and our ongoing corporate development work, including bringing critical business perspectives to our current patent estate. Mike has also served as the company’s executive team project lead for our ocular program since its inception within Aurinia. In addition to being one of the co-founders of Aurinia, Mike was previously CEO and Director of the privately held Aurinia Pharmaceuticals Inc., which merged with Isotechnika back in 2013, helping to bring the company into a structure capable of advancing voclosporin towards an approval. Mike spearheaded a tremendously complex transaction within a tripartite settlement agreement to form the modern-day Aurinia. This provided the foundation for Aurinia to close multiple financing rounds over the past seven years. During the early days Aurinia, he was a key player in multiple early-stage bridge financing rounds that were necessary for the company’s survival. Mike joined Aurinia after working for Vifor Pharma where he was Director, Global Business Development & Licensing. Prior to Vifor, Michael was a key member of the business development team that saw Aspreva sold to Galenica for $915 million. Upon joining Aspreva in 2004, Mike initiated the global strategic launch planning process for CellCept® in “less-common” autoimmune diseases, including lupus nephritis. Prior to this, Mike was already a seasoned pharma executive holding a variety of progressively senior commercial positions at Schering-Plough, including being responsible for the Immunology Business Unit in France, which included the launch of Remicade® across multiple indications. Michael started his career in the industry in the sales organization of Schering-Plough, where he received multiple awards and recognition while rapidly progressing towards the prior mentioned roles.
Chief Financial Officer
Joe Miller joins Aurinia with over two decades of experience as a senior executive managing financial operations and supporting enterprise growth in companies across the health sciences, biotech and pharmaceutical sectors. Most recently, he served as Chief Financial Officer, Principal Executive Officer, and Corporate Secretary at Cerecor, Inc. At Cerecor, he completed the acquisition of Ichorion Therapeutics, Inc., the purchase of Aevi Genomic Medicine, and facilitated a strategic transformation of the organization by leading the divestiture of the company’s commercial portfolio in a transaction with Aytu BioScience, Inc. in 2019. Joe currently serves as a director on Cerecor’s Board. Prior to Cerecor, Joe was the Vice President of Finance at Sucampo Pharmaceuticals, Inc., where he was responsible for building out the finance organization to effectively support the company’s rapid growth, ultimately leading to the $1.2B merger with Mallinckrodt in early 2018. Prior to Sucampo, he served in various progressive finance and management roles at QIAGEN, Eppendorf and KPMG LLP. Joe received his B.S. in accounting from Villanova University and is a Certified Public Accountant.
Executive Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer
Stephen Robertson brings more than 13 years of corporate law experience across various roles to Aurinia. Most recently he served as Partner with the law firm Borden Ladner Gervais LLP since 2014. He holds significant corporate legal experience across a number of industries including life sciences. Stephen is experienced in securities, corporate and commercial legal matters, including extensive experience with mergers and acquisitions, commercial agreements and corporate governance matters. Stephen has also been recognized with a number of awards and honors including being part of the 2020 edition of the Best Lawyers in Canada for Securities Law. In addition, he is an Adjunct Professor at the Allard School of Law of the University of British Columbia. He received his Bachelor of Laws degree from the University of Manitoba.